Neutropenia—a condition marked by abnormally low white blood cell counts—imposes a significant economic burden on U.S. healthcare systems for patients undergoing treatment for metastatic breast cancer (mBC), according to a retrospective claims analysis using the IQVIA PharMetrics Plus database. Data covering September 2019 to June 2024 reveals that neutropenia-related costs account for up to 18% of total monthly expenditures for patients receiving specific metastatic therapies, highlighting an urgent need for cost-effective management strategies.
How does treatment type influence neutropenia costs?
The financial impact of neutropenia varies sharply depending on the therapeutic regimen. According to the retrospective study, patients with HR-positive/HER2-negative mBC receiving sacituzumab govitecan (SG) faced the highest all-cause costs at $44,921 per patient per month (PPPM), with $8,046 (18%) specifically attributed to neutropenia. In contrast, those on endocrine therapy (ET) incurred total costs of $6,110 PPPM, with only $75 (1%) linked to neutropenia.
Neutropenia-related inpatient visits were most frequent among HR-positive/HER2-negative patients receiving SG, with 18% of patients requiring hospitalization, compared to 0% for those on endocrine therapy.
What is the economic burden for mTNBC patients?
Metastatic triple-negative breast cancer (mTNBC) presents unique challenges in resource utilization. Research indicates that mTNBC patients on SG regimens experienced all-cause costs of $44,568 PPPM, with 17% ($7,720) tied to neutropenia. For those on targeted therapy (TT), the neutropenia-related cost was $1,825 PPPM, representing 8% of the total $25,980 monthly spend. These figures underscore the financial strain that managing treatment-related adverse events places on both patients and providers.
Why does neutropenia frequency vary by therapy?
The frequency of neutropenia is directly linked to the intensity of the treatment regimen. Analysis of the IQVIA database found that 48.5% of HR-positive/HER2-negative patients on SG experienced neutropenia, compared to just 8.8% of those on ET. Among the mTNBC cohort, neutropenia rates were 43.9% for SG, 36.1% for chemotherapy, and 39.4% for targeted therapy. This variance suggests that clinicians must weigh the efficacy of high-potency treatments against the higher risk and cost of managing subsequent hematological toxicities.
Pro Tip: Managing Resource Utilization
Healthcare providers can potentially mitigate the financial impact of neutropenia by optimizing early intervention strategies. According to the study, high rates of outpatient visits—reaching as high as 40% for mTNBC patients on SG—suggest that proactive monitoring could reduce the need for more expensive, acute inpatient care.
Frequently Asked Questions
What is the primary cause of the economic burden in mBC patients?
The economic burden is driven by both the high cost of advanced metastatic therapies and the additional costs associated with managing adverse events like neutropenia, including inpatient and outpatient medical visits.
Are all breast cancer treatments equally likely to cause neutropenia?
No. The study shows that neutropenia rates range from 8.8% for endocrine therapy to 48.5% for sacituzumab govitecan, indicating that risk profiles differ significantly by drug class.
Why is this data important for future care?
Identifying the specific cost contribution of neutropenia helps health systems evaluate the “value” of new treatments, balancing clinical benefits against the total cost of care.
Have questions about how these findings might impact patient care protocols? Join the conversation in the comments section below or subscribe to our oncology newsletter for the latest clinical updates.
Related reading